Simplify Logo

Full-Time

Senior Manager

Biostatistics

Posted on 7/29/2024

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS cancers

Biotechnology
Healthcare

Compensation Overview

$185k - $220kAnnually

+ Equity Awards + Benefits + Learning and Development Opportunities

Senior, Expert

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Public Health
Biology & Biotech
Requirements
  • Ph.D. or M.S. in Statistics/Biostatistics, minimum 3 years (for Ph.D.) and 6 years (for M.S.) of experience in biotech/pharma industry as a statistician. Level will be determined based on the relevance of experience.
  • Oncology drug development experience is a must.
  • Ability to work independently and within a team.
  • Excellent verbal and written communication skills are required.
Responsibilities
  • Provide statistical expertise for design, analysis and reporting of clinical or pre-clinical studies
  • Collaborate with various functions on study design and planning, protocol development, statistical methodology and analysis.
  • Develop statistical analysis plans and analysis specifications.
  • Collaborate with statistical programming to ensure that analysis is conducted per statistical plan and specifications.
  • Collaborate with data management and clinical operations to ensure robust CRF and database development and quality data collection.
  • Collaborate with clinical pharmacology, translational medicine and other pre-clinical groups to provide statistical input and support as needed.
  • Collaborate in publications, assist in data interpretation, and ensure consistency and accuracy in data presentation
  • Contribute to the development of functional-level standards, SOPs, and templates.
  • Represent biostatistics on study/project teams.

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main products are RASON Inhibitors, designed to inhibit the activity of RAS proteins that promote cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses specifically on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$1.3B

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

18%

1 year growth

44%

2 year growth

131%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE